Session 1: Illuminating the challenge and highlighting the opportunity for creating new medicines
Chair: Adrian Carter, Boehringer Ingelheim, Germany

Tudor Oprea - University of New Mexico, USA

Heiko Runz - Biogen, USA

Chemical probes and the chemical biology of cancer
Paul Workman - CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK

The challenges of creating new medicines: Joining forces to discover novel biological tools and apply new therapeutic modalities
Alleyn Plowright - Sanofi, Germany

Coffee break

Session 2: Illuminating the most promising proteins by virtue of druggability, human genetics and bioinformatics
Chair: Patrick Aloy, IRB Barcelona, Spain

Eytan Ruppin - National Cancer Institute, USA

Selected short talk

Kristin Brown - GlaxoSmithKline, UK

Judith Zaugg - EMBL Heidelberg, Germany

Patrick Aloy - IRB Barcelona, Spain

Poster Session with beer and snacks
ATC Helices

Dinner

Session 3: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 1
Chair: Gerard Drewes, Cellzome, a GlaxoSmithKline company, Germany

Giulio Superti-Furga - Center for Molecular Medicine, Austria

Selected short talk

Selected short talk

Stefan Knapp - Goethe University Frankfurt, Germany

Coffee break

Anne-Claude Gavin - University of Geneva, Switzerland

Selected short talk

Innate DNA sensing mechanisms in health and disease
Andrea Ablasser - EPFL, Switzerland

Meet the speakers and lunch

Session 4: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 2
Chair: Anke Müller-Fahrnow, Bayer AG, Germany

Kai Johnsson - Max Planck Institute for Medical Research, Germany 

Chemical physiology of natural products and antibody conjugates
Gonçalo Bernardes - University of Cambridge, UK and iMM Lisboa, Portugal

Training native electrophiles for covalent drug development
Yimon Aye - EPFL, Switzerland

Anke Müller-Fahrnow - Bayer AG, Germany

Coffee break

A systems approach to functional precision medicine by deep learning and multi-OMICs
Berend Snijder - ETH Zürich, Switzerland

Maurizio Pellecchia - University of California, Riverside, USA

Selected short talk

Christine Donahue - GlaxoSmithKline, USA

Coffee break

Session 7: New engineering approaches for breaking the druggability barrier
Chair: Anne-Claude Gavin, University of Geneva, Switzerland

Fragment-based covalent ligand screening to target the ubiquitin system
Katrin Rittinger - The Francis Crick Institute, UK

Structure based PROTAC design to expand the druggable Proteome
Alessio Ciulli - University of Dundee, UK

Chemical probes in target discovery
Paul Brennan - University of Oxford, UK

Identifying gut microbiome contributions to drug metabolism
Michael Zimmermann - EMBL Heidelberg, Germany

End of conference
Packed lunch and departure